(Q46720746)

24 December 2017

title

Resistance to pretransplant imatinib therapy may adversely affect the outcome of allogeneic stem cell transplantation in CML. (English)

1 reference

24 December 2017

1 reference

Weisser M

1

1 reference

24 December 2017

Schmid C

2

1 reference

24 December 2017

Schoch C

3

1 reference

24 December 2017

Hiddemann W

4

1 reference

24 December 2017

Kolb HJ

5

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

24 December 2017

Bone Marrow Transplantation

published in

1 reference

24 December 2017

volume

36

1 reference

24 December 2017

issue

11

1 reference

24 December 2017

page(s)

1017-1018

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705172

exact match

0 references

cites work

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705172

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705172

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705172

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705172

21 January 2018

Identifiers

DOI

10.1038/SJ.BMT.1705172

1 reference

24 December 2017

PubMed ID

16184176

1 reference

24 December 2017